BioSpace News Archive

Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company focused on discovering and developing medicines that are transformational for patients, today announced that members of its management team will participate in a fireside chat at the virtual SVB Securities Global Biopharma Conference on Tuesday, February 14, 2023 at 8:00 a.m. ET.

Mersana Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates targeting cancers in areas of high unmet medical need, announced that members of management will present at the following upcoming investor conferences:

Protara Therapeutics, Inc. announced that management will participate in a fireside chat at the Guggenheim Healthcare Talks Oncology Day on Thursday, February 9, 2023 at 11:20 am ET in New York, New York.

IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD) announced today its financial results for the fourth quarter and year ended December 31, 2022.

Volta Medical today announced the completion of patient enrollment in the randomized controlled clinical trial, TAILORED-AF, evaluating VX1-guided ablation compared to a ‘standard of care’ anatomical ablation approach.

Singular Genomics Systems, Inc. today announced its G4 Sequencing Platform demonstrated compatibility with the 10x Genomics’ Chromium Single Cell platform through the 10x Compatible Partner Program (CPP).

Ada Health Inc. (‘Ada’) today announces the launch of its first digital condition-based care journey, designed to help people understand if they meet current criteria for progression to severe COVID-19 and connect with a health care provider for evaluation of their COVID-19 symptoms and treatment options.

The I3LUNG project funded by the European Commission and promoted by MEDSIR, an independent clinical research company in oncology based in Barcelona, the Instituto Nazionale dei Tumori in Milan and other European institutions has launched a new website.

RefleXion Medical, a therapeutic oncology company, today announced the U.S. Food and Drug Administration (FDA) has granted the first marketing clearance for its SCINTIX™ biology-guided radiotherapy, a cutting-edge treatment applicable for early and late-stage cancers.

OM1 a leading real-world data, outcomes and technology company with a focus on chronic diseases, today announced the launch of its Reasons for Discontinuation (RfD) Analytic Reports.